2022
Emerging Concepts in Defective Macrophage Phagocytosis in Cystic Fibrosis
Jaganathan D, Bruscia EM, Kopp BT. Emerging Concepts in Defective Macrophage Phagocytosis in Cystic Fibrosis. International Journal Of Molecular Sciences 2022, 23: 7750. PMID: 35887098, PMCID: PMC9319215, DOI: 10.3390/ijms23147750.Peer-Reviewed Original ResearchConceptsPhagosome formationCystic fibrosis transmembrane conductance regulator (CFTR) geneTransmembrane conductance regulator geneInnate immunityTissue homeostasisRegulator geneMutant CFTRCF macrophagesCystic fibrosisPhagocytic mechanismsPathogenic microbesAdaptive immune systemDefective macrophage phagocytosisCFTRCurrent understandingTherapeutic developmentCentral roleMacrophage phagocytosisCFTR modulatorsPhagocytic cellsPhagocytosisNew therapeutic developmentsMacrophages contributesLung functionChronic inflammation
2016
Cellular Innate Immunity: An Old Game with New Players
Gasteiger G, D'Osualdo A, Schubert DA, Weber A, Bruscia EM, Hartl D. Cellular Innate Immunity: An Old Game with New Players. Journal Of Innate Immunity 2016, 9: 111-125. PMID: 28006777, PMCID: PMC6738785, DOI: 10.1159/000453397.Peer-Reviewed Original ResearchConceptsInnate immunityMyeloid-derived suppressor cellsInnate lymphoid cellsInnate immune cellsAdaptive immune responsesNovel therapeutic opportunitiesCell typesSuppressor cellsImmune cellsImmune responseLymphoid cellsTherapeutic opportunitiesInfectious diseasesCurrent conceptsMolecular pathwaysImmunityCellsNovel cell typesInflammasomeDisease
2015
Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation
Zhang PX, Cheng J, Zou S, D'Souza AD, Koff JL, Lu J, Lee PJ, Krause DS, Egan ME, Bruscia EM. Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. Nature Communications 2015, 6: 6221. PMID: 25665524, PMCID: PMC4324503, DOI: 10.1038/ncomms7221.Peer-Reviewed Original ResearchConceptsCF macrophagesMiR-199aMicroRNA-199aHyper-inflammatory responseCFTR-deficient miceCystic fibrosis patientsCystic fibrosis lungLung destructionDisease morbidityPharmacological modulationCF miceCF lungFibrosis patientsInnate immunityLungMacrophagesCAV1 expressionDrug celecoxibReduced levelsTLR4CelecoxibMiceCav1PathwayMorbidity
2012
Innate immunity in cystic fibrosis lung disease
Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Döring G. Innate immunity in cystic fibrosis lung disease. Journal Of Cystic Fibrosis 2012, 11: 363-382. PMID: 22917571, DOI: 10.1016/j.jcf.2012.07.003.Peer-Reviewed Original ResearchConceptsLung diseaseCF lung diseaseInnate immunityChronic infective lung diseaseNovel immune-targeted therapiesCystic fibrosis lung diseasePulmonary immune responseChronic lung diseaseImmune-targeted therapiesPro-inflammatory cascadeInfective lung diseaseInnate immune regulationInnate immune systemCystic fibrosis patientsPotential clinical relevanceEpithelial dysfunctionLeukocyte recruitmentImmune regulationImmune responseAdaptive immunityClinical relevanceFibrosis patientsImmune systemDiseaseImmunity